The FDA approved rituximab and hyaluronidase human (Rituxan Hycela, Genentech) for subcutaneous injection for the treatment of adults with the following blood cancers: previously untreated and relapsed or refractory follicular lymphoma (FL), previously untreated diffuse large B-cell lymphoma (DLBCL) and previously untreated and previously treated chronic lymphocytic leukemia (CLL).
Significant Information:
- Treatment can be administered in 5 to 7 minutes, compared with 1.5 hours or more for IV